Proffered paper highlights 1
- Factors influencing adjuvant treatment choices in stage I seminoma: the patients’ perspective
- Combining peptide vaccination with immunostimulatory monoclonal antibodies provides potent immunotherapy in neuroblastoma
- Does place of death from lung, colorectal, breast, and prostate cancer vary between ethnic groups?
- Benefit of radiotherapy dose escalation in localised prostate cancer with respect to expression of intrinsic markers of hypoxia
- Pharmacokinetic and pharmacodynamic Phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition
- The second anal cancer trial (ACT2): a randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus
- ESPAC-3(v2): a multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma
- Abstract to be confirmed
